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ABSTRACT
A previous case-control study reported that an in-vitro interferon (IFN)-c response to early secreted
antigenic target (ESAT)-6 selected peptides was associated with active tuberculosis (A-TB). The objective
of the present pilot study was to evaluate the diagnostic accuracy of this assay for TB disease in a clinical
setting. An IFN-c ELISPOT assay was performed on samples from patients with suspected A-TB using
two peptides selected from ESAT-6 protein and three peptides selected from culture filtrate 10 (CFP-10)
proteins. The results were compared with those obtained by two commercially available assays
approved for diagnosis of TB infection (T SPOT-TB and QuantiFERON-TB Gold) which use ESAT-
6 ⁄CFP-10 (RD1) overlapping peptides. Sensitivity to the RD1 selected peptides was 70% (positive for 16
of 23 patients with microbiologically diagnosed A-TB) and specificity was 91% (positive for three of 32
controls). In contrast, the sensitivity and specificity were 91% and 59%, respectively, for T SPOT-TB, and
were 83% and 59%, respectively, for QuantiFERON-TB Gold. The RD1 selected peptides assay had the
highest diagnostic odds ratio for A-TB. Thus, the results suggest that an assay based on RD1 selected
peptides has a higher diagnostic accuracy for A-TB in a clinical setting compared with commercially
available assays based on RD1 overlapping peptides.
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INTRODUCTION
Epidemiological surveys suggest that one-third of
the world’s population is infected with Mycobac-
terium tuberculosis [1]. Primary infection leads to
active tuberculosis (A-TB) in a minority (c. 10%)
of infected individuals [2], usually within 2 years.
In the remaining cases, the immune system
contains the infection, and the individual is
non-infectious and symptom-free [1]. This clinical
latency can persist throughout an individual’s
lifetime. However, in some circumstances, the
host immune response is perturbed and latent
tuberculosis infection (LTBI) may develop into
post-primary A-TB. This process can occur, for
example, following infection with human
immunodeficiency virus (HIV), malnutrition, use
of steroids or other immunosuppressive medica-
tions, or because of advanced age [3].
Development of new diagnostic tools would
improve the control of tuberculosis (TB) by
improving diagnosis of A-TB and by allowing a
more accurate identification of LTBI [4]. Until
recently, the tuberculin skin test (TST) has been
the only tool available for diagnosing TB infec-
tion. However, this test is limited by its low
sensitivity (75–90%) in diagnosing A-TB [5–7],
and its low specificity, caused by the fact that the
purified protein derivative (PPD) used for skin
testing contains > 200 antigens that are shared
widely among environmental mycobacteria [5–7]
and the Mycobacterium bovis BCG strain used for
vaccination. Lastly, TST does not allow discrim-
ination between A-TB and LTBI [5].
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In an effort to develop more accurate tools for
immunological diagnosis of TB, several studies
have been performed to investigate early secreted
antigenic target 6 (ESAT-6) and culture filtrate 10
(CFP-10) proteins [8–10]. These proteins, encoded
by genes located within the region of difference 1
(RD1) of the M. tuberculosis genome, are much
more specific for M. tuberculosis than is PPD, as
they are not shared with BCG substrains or with
most environmental mycobacteria (with the
exception of Mycobacterium kansasii, Mycobacteri-
um szulgai, Mycobacterium flavescens and
Mycobacterium marinum). Peripheral blood mono-
nuclear cells (PBMCs) of patients with TB [11,12],
or of household contacts of TB patients [13],
release interferon (IFN)-c when exposed in vitro to
either ESAT-6 or CFP-10 intact proteins, or to
overlapping peptides spanning the length of
these antigens.
The above studies resulted in the development
of two commercially available tests (QuantiFER-
ON-TB Gold and T SPOT-TB) that have been
approved for the diagnosis of TB infection [10,14].
Both tests are based on ESAT-6 and CFP-10
overlapping peptides spanning the whole pro-
teins, and employ ELISA or ELISPOT techniques.
Although these assays provide an accurate diag-
nosis of M. tuberculosis infection, they do not
discriminate between A-TB and LTBI. Thus, a
positive response to these tests requires further
clinical investigation to rule out A-TB.
In this context, an IFN-c ELISPOT assay was
designed, based on multi-epitopic peptides from
the ESAT-6 protein, selected by quantitative
implemented analysis of HLA peptide-binding
motifs. A positive response with this assay was
observed for most A-TB patients, while no
response was observed with controls, even
among TST-positive non BCG-vaccinated indi-
viduals [15]. Comparable observations were
made with a whole-blood assay in which new
CFP-10 selected peptides were tested [16].
Moreover, after therapy for 3 months, the IFN-
c response became undetectable in those pa-
tients who responded to treatment [17]. These
data suggested that the response to ESAT-6 and
CFP-10 selected peptides may be associated
specifically with A-TB, but were obtained in
case-control studies which tend to overestimate
diagnostic accuracy [18].
The objective of the present pilot study was
to evaluate whether an in-vitro assay based on
RD1 selected peptides is potentially useful for
the diagnosis of A-TB in a clinical setting. Thus,
consecutive patients enrolled prospectively with
suspicion of pulmonary TB were studied. The
assay was performed using ESAT-6 ⁄CFP-10
(RD1) intact proteins and selected peptides
[15–17], and the results obtained were compared
with those obtained using two commercially
available tests based on RD1 overlapping pep-
tides that have been approved for in-vitro
immunological diagnosis of TB infection.
MATERIALS AND METHODS
Patient population and study design
Patients admitted to the infectious and respiratory diseases
wards at the National Institute for Infectious Diseases
(INMI) ‘L. Spallanzani’ (Rome, Italy) between April 2004
and November 2004 were included in the study if there was
a clinical suspicion of TB according to the institutional
protocol, i.e., a chest radiograph suggestive of A-TB, with
upper lobe infiltrates, cavitary lesions, hilar lymphadenopa-
thy and miliary pattern, and ⁄ or other signs and symptoms
suggestive of A-TB, including fever, persistent cough, haem-
optysis or weight loss [19]. Other criteria for inclusion were
a negative HIV test and the absence of therapy with
immunosuppressive drugs. Patients included in the study
underwent clinical and microbiological examinations to
confirm or exclude the diagnosis of A-TB. In brief, sequen-
tial respiratory samples (three expectorated or two induced
sputa) during the first 7 days following hospital admission
were collected. An acid-fast bacilli (AFB) smear examination
(Ziehl-Neelsen) and culture, both on Lowenstein-Jensen
medium and in a BACTEC 460 (Becton Dickinson, Sparks,
MD, USA) with Middlebrooks 7H10 ⁄ 7H11 medium, were
performed for each specimen. A chest radiograph and a
TST, administered by the Mantoux method (5 Tuberculin
Units), were performed for each patient. Individuals with a
TST induration ‡ 10 mm in size were classified as TST-
positive [5–7].
Patients were classified as having A-TB if the diagnosis was
confirmed by isolation of M. tuberculosis from biological
specimens. For controls, patients were chosen who were
admitted with suspected A-TB, but who subsequently yielded
sputa negative by AFB smear and culture for M. tuberculosis,
with either a resolution of clinical symptoms and radiographic
abnormalities following antibiotic therapy not involving drugs
active against M. tuberculosis, or who presented with an
alternative diagnosis (e.g., lung cancer).
Within 7 days of admission, and before starting anti-TB
therapy, an EDTA blood sample was obtained from all
enrolled individuals. An ELISPOT assay, based on RD1
selected peptides and intact proteins, was performed in
parallel with the commercially available assays (QuantiFER-
ON-TB Gold, Cellestis Ltd, Carnegie, Victoria, Australia; T
SPOT-TB, Oxford Immunotec, Oxford, UK). Clinicians were
unaware of the results of the in-vitro assays, and laboratory
personnel were unaware of the clinical status of the patient.
The study was approved by the local Ethics Committee, and all
patients enrolled gave written informed consent.
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Peptide selection and ELISPOT assay
The selection of HLA-class II restricted epitopes of ESAT-6 and
CFP-10 M. tuberculosis proteins was performed by quantitative
implemented analysis of HLA peptide-binding motifs, as
described previously for ESAT-6 [15–17]. Peptides were
synthesised as free amino-acid termini using Fmoc chemistry
(ABI, Bergamo, Italy). Lyophilised peptides were diluted in
dimethyl sulphoxide (DMSO) at stock concentrations for each
peptide of 10 mg ⁄mL, and were stored at )80C. RD1 peptides
used in this study are listed in Table 1.
PBMCs were separated and stimulated as described previ-
ously [15–17]. In brief, cell cultures were treated in duplicate
with: (i) a pool of the two ESAT-6 peptides (each at 25 mg ⁄L);
(ii) a pool of the three CFP-10 peptides (each at 2 mg ⁄L); (iii)
phytohaemagglutinin (PHA) (Sigma, St Louis, MO, USA) at
5 mg ⁄L; and (iv) ESAT-6 and CFP-10 intact proteins (Lionex,
Braunschweig, Germany) at 1 mg ⁄L.
Scoring of results
Results were scored as negative if the average of the raw
number of spot-forming cells (SFCs) of cultures stimulated
with PHA, ESAT-6 and CFP-10 (RD1) intact proteins and
peptides was < 10. Results were scored as positive for RD1
peptides if the average number of SFCs was ‡ two-fold higher
for the ESAT-6 peptide pool, or four-fold higher for the CFP-10
peptide pool, compared with the average number of SFCs for
the corresponding controls. Results were scored as positive for
PHA and RD1 intact proteins if the average number of SFCs in
cultures stimulated with these antigens was ‡ three-fold higher
than the average number of SFCs for the corresponding
controls. A cut-off value was defined by constructing a
receiver operator characteristic (ROC) curve to maximise the
diagnostic accuracy for active tuberculosis. In this analysis,
performed with LABROC-1 software (University of Chicago,
Chicago, IL, USA), 34 SFCs ⁄million PBMCs for RD1 peptide
pools, and 36 SFCs ⁄million PBMCs for intact proteins, were
identified as the values maximising the sum of the specificity
and sensitivity for A-TB. A concordance of 100% was found
between the two scoring methods; therefore, the cut-off value
was used to score the results.
Results are presented as the number of SFCs ⁄million
PBMCs, after subtraction of the appropriate control according
to the criteria described above [15–17].
Statistical analysis
The mean ± SD was calculated. Differences among groups
were evaluated with the Mann–Whitney U-test, while the
McNemar test was used to compare the results of the different
assays. Analysis was carried out with SPSS v.11 for Windows
(SPSS Inc., Chicago, IL, USA). To provide a global meas-
ure of the accuracy of immunological assays for the diagnosis
of A-TB, the diagnostic odds ratio was calculated for each
assay, defined as the odds of a positive test among patients
with A-TB divided by the odds of a positive test among
patients without A-TB.
RESULTS
Evaluation of response to RD1 selected
peptides and intact proteins by ELISPOT assay
Fifty-five patients were enrolled in the study
(Table 2). TB diagnosis was confirmed microbio-
logically for 23 patients, and ruled out for 32
patients, 18 of whom were TST-positive and 14 of
whom were TST-negative. When patient speci-
mens were analysed by ELISPOT assay using the
RD1 selected peptides, the number of IFN-c SFCs
was significantly higher (131 ± 24) in patients
with A-TB compared with controls (27 ± 13;
p < 0.0001). This difference was statistically sig-
nificant, independent of whether the controls
Table 1. CD4+ T-cell epitopes in
ESAT-6 and CFP-10 proteins selec-
ted to be broadly recognised in
patients with active tuberculosis
Protein Position Sequence DR-serological specificities covereda
ESAT-6 6–28 WNFAGIEAAASAIQGNVTSIHSL 1, 3, 4, 8, 11(5),
13(6), 52, 53
ESAT-6 66–78 NALQNLARTISEA 3, 8, 11(5), 13(6), 15(2), 52
CFP-10 18–31 FERISGDLKTQIDQ 3, 5, 11(5), 52
CFP-10 43–70 GQWRGAAGTAAQAAVVRFQEAANKQKQE 1, 3, 4, 7, 8, 11(5), 13(6), 15(2), 52
CFP-10 74–86 TNIRQAGVQYSRA 3, 4, 7, 8, 11(5),
12(5), 13(6), 15(2)
aListed are the HLA-class II allele specificities to which the selected peptides are able to bind.
CD, cluster of differentiation; ESAT, early secreted antigenic target; CFP, culture filtrate protein; HLA, human
leukocyte antigen.
Table 2. Epidemiological and demographic characteristics
of patients enrolled with a suspicion of active pulmonary
tuberculosis (TB)
Active TB
patients
Control patients
TST-positive TST-negative
Total (n) 23 18 14
Mean age ± SE (years) 33 ± 2 44 ± 3 38 ± 4
Gender
Female (n) 8 6 7
Male (n) 15 12 7
Country of birth
Western Europe (n) 5 16 9
Eastern Europe (n) 10 2 2
Africa (n) 4 – 2
Asia (n) 2 – 1
South America (n) 2 – –
CD4 cell count ± SE 971 ± 149 993 ± 93 853 ± 314
BCG-vaccinated (n) 18 4 4
Diseases other than TB
Bacterial pneumonia (n) – 7 8
Bronchitis (n) – 4 4
Fever of unknown origin (n) – 2 2
Bacterial pleuritis (n) – 1 –
Pulmonary carcinoma (n) – 3 –
Pseudo-tumour (n) – 1 –
TST, tuberculin skin test; SE, standard error; BCG, Bacillus Calmette et Guerin
vaccine; CD, cluster of differentiation.
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were TST-positive (44 ± 23; p < 0.0001) or TST-
negative (6 ± 2; p < 0.0001) (Fig. 1A).
The response to RD1 selected peptides was
scored as positive for 16 (70%) of the 23 A-TB
patients and for three (9%) of the 32 controls
(3 ⁄ 18 TST-positive and 0 ⁄ 14 TST-negative). Thus,
the sensitivity of this assay for A-TB in the
population studied was 70%, and the specificity
was 91% (Table 3). The RD1 intact proteins were
used as an internal control. The number of IFN-c
SFCs was significantly higher in patients with
A-TB (181 ± 27) compared with controls
(77 ± 18); this difference remained significant
when compared with the TST-negative controls
(13 ± 4; p < 0.0001), but not when compared with
the TST-positive controls (114 ± 23; p 0.1)
(Fig. 1B). A positive response to RD1 intact
proteins was observed in 19 (83%) of the 23 A-
TB patients and in 14 (44%) of the 32 controls.
Thus, the sensitivity of the assay for A-TB was
83% and the specificity was 66% (Table 3).
When considering patients with A-TB, the
proportion of positive responses to RD1 intact
proteins did not differ significantly from that of
the RD1 selected peptides (p 0.37). In contrast,
controls were significantly more likely to respond
to RD1 intact proteins than to RD1 selected
peptides (p 0.001), and the statistical significance
was even greater (p 0.0001) if only TST-positive
controls were considered.
Comparison of IFN-c ELISPOT response to
RD1 selected peptides and intact proteins
with assays approved for the diagnosis of TB
infection
To substantiate the data, the results were com-
pared with those obtained by T SPOT-TB and
QuantiFERON-TB Gold (Table 3). A positive
response to T SPOT-TB was observed with 21
(91%) of the 23 A-TB patients and with 13 (41%)
of the 32 controls. A positive response to Quan-
tiFERON-TB Gold was observed with 19 (83%) of
the 23 A-TB patients and with 13 (41%) of the 32
controls.
When the peptide responses were examined
specifically in patients with A-TB, the proportion
of positive responses to RD1 selected peptides
was slightly lower compared with overlapping
peptides, but the differences were not statistically
significant (p 0.5 compared with both T SPOT-TB
and QuantiFERON-TB Gold). However, when
considering controls, the proportion of positive
responses was significantly higher for T SPOT-TB
and QuantiFERON-TB Gold than for the RD1
selected peptides assay (p 0.002 for both compar-
isons). This difference was still statistically signi-
ficant when TST-positive controls were
considered separately (p 0.002 and p 0.004 com-
pared with T SPOT-TB and QuantiFERON-TB
Gold, respectively). In contrast, no significant
difference in the proportion of positive responses
compared to overlapping peptides (T SPOT-TB
and QuantiFERON-TB Gold) was found among
either A-TB patients or controls when intact
proteins were studied.
Fig. 1. IFN-c response to RD1 selected peptides in active
tuberculosis (A-TB) patients and controls. Detection of
IFN-c was by the ELISPOT assay. The highest response to
(A) RD1 selected peptides, and (B) RD1 intact proteins in
terms of specific interferon (IFN)-c-secreting T-cells is
reported as spot-forming cells (SFCs) per million periph-
eral blood mononuclear cells (PBMCs) for each individual.
Horizontal bars represent the mean of the SFCs for each
group of patients. p values denote the difference among
the responders in each group of patients.
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According to these data, the RD1 selected
peptides ELISPOT assay had the highest diagnos-
tic odds ratio for A-TB (Table 4). All of the assays
performed similarly in identifying A-TB, but only
the RD1 selected peptides assay may distinguish
between A-TB and LTBI.
DISCUSSION
This pilot study assessed an assay based on RD1
selected peptides and intact proteins for the
diagnosis of A-TB in a clinical setting. The
ELISPOT technique was used to enumerate IFN-
c-secreting T-cells in response to these M. tuber-
culosis antigens. Use of selected peptides [15–17]
gave a sensitivity for A-TB of 70% and a specif-
icity of 91%. The accuracy of the response to RD1
selected peptides for active disease, as measured
by the diagnostic odds ratio, was higher than for
RD1 overlapping peptides used in tests approved
for TB diagnosis (T SPOT-TB and QuantiFERON-
TB Gold) [10,14].
Using an RD1 selected peptides immune assay,
a slightly higher sensitivity among patients with
A-TB has been reported [15–17]. However, the
present study enrolled a consecutive series of
patients recruited on the basis of suspected
pulmonary A-TB, whereas the previous study,
as well as others [20,21], used a case-control
design, which can overestimate the diagnostic
accuracy [18].
The immune assays based on overlapping
peptides tended to have a higher sensitivity,
although the difference with the RD1 selected
peptides assay was not statistically significant.
Importantly, four of the seven A-TB patients who
did not give a positive response with the RD1
selected peptides were probably in a condition of
‘M. tuberculosis-specific immune unresponsive-
ness’, as they did not respond either to RD1 intact
proteins or to the commercially available assays.
However, it is important to note that patients with
A-TB, as well as the controls, were all HIV-
negative and were not receiving ongoing immuno-
suppressive therapy. An in-vitro response to the
positive control, i.e., the mitogen PHA, was
observed in all patients enrolled in the study,
and similar CD4 cell counts were found among
the groups of patients. Thus, the absence of
response to RD1 antigens may also be explained
as a consequence of the intrinsic limits of immune
diagnostic assays, and is consistent with data
published for patients with A-TB showing a 70%
positive response to the RD1 ELISPOT assay [22].
An important feature of the RD1 selected
peptides assay appears to be its specificity for
A-TB, a characteristic that differentiates this test
from other immune diagnostic assays designed to
Table 3. Comparison of the different assays for immune diagnosis of tuberculosis (TB)
Assay
Active TB patients Control patients
TST-positive TST-negative Total
Positive response
over total (%)
Positive response
over total (%)
Positive response
over total (%)
Positive response
over total (%)
RD1 ELISPOT assay Selected peptides 16 ⁄ 23 (70) 3 ⁄ 18 (17) 0 ⁄ 14 (0) 3 ⁄ 32 (9)
Intact proteins 19 ⁄ 23a (83) 14 ⁄ 18b (78) 0 ⁄ 14 (0) 14 ⁄ 32b (44)
RD1 commercially
available assays
T SPOT-TB 21 ⁄ 23a (91) 13 ⁄ 18b (72) 0 ⁄ 14 (0) 13 ⁄ 32b (41)
QuantiFERON-TB Gold 19 ⁄ 23a (83) 13 ⁄ 18b (72) 0 ⁄ 14 (0) 13 ⁄ 32b (41)
RD1, region of difference; TST, tuberculin skin test.
ap > 0.05 compared with RD1 selected peptides assay.
bp < 0.01 compared with RD1 selected peptides assay.
Table 4. Sensitivity, specificity and
diagnostic odds ratio of the RD1
selected peptides assay for A-TB
and control patients compared with
the T SPOT-TB and QuantiFERON-
TB Gold assays
Assay
Sensitivity
(95% Cl)
Specificity
(95% Cl)
Diagnostic OR
(95% Cl)
RD1 ELISPOT assay Selected peptides 70% 91% 22
(47–87) (75–98) (5–97)
Intact proteins 83% 56% 6
(61–95) (38–74) (2–22)
RD1 commercially T SPOT-TB 91% 59% 15
available assays (72–99) (41–76) (3–77)
QuantiFERON-TB Gold 83% 59% 7
(61–95) (41–76) (2–25)
A-TB, active tuberculosis; RD1, region of difference.
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identify M. tuberculosis infection. The specificity of
the RD1 selected peptides assay for active TB was
91%, compared with significantly lower figures
for assays using RD1 intact proteins (56%) or
overlapping peptides (59%). These data agree
with a study based on the use of RD1 intact
proteins in a clinical setting [23]. The results
obtained using RD1 intact proteins were essen-
tially in agreement with those obtained with the
commercially available assays using RD1 over-
lapping peptides. Thus, the association of the
assay results with A-TB is probably caused by
the use of RD1 selected peptides rather than the
particular assay format.
At present, the reason for the differences in the
response to the selected peptides and the over-
lapping peptides remains unclear, but could be
related to the variable immunological status of the
patients with A-TB and LTBI, or the selection of
the cut-off value by ROC analysis (aimed at
maximising the accuracy of the diagnosis of A-
TB). Regarding the immune status of the patients,
it is thought that metabolically active and viable
bacilli secrete proteins, e.g., ESAT-6 and CFP-10
[24]. Consequently, IFN-c-producing T-cells spe-
cific to the selected epitopes are also present at
high frequency only during the active replication
of mycobacteria. Previous reports have demon-
strated that lymphocytes with immediate effector
memory function circulate for a limited time until
the antigen has been cleared [25]. Therefore, the
frequency of T-cells specific to the single epitopes
contained in the selected peptides might decrease
dramatically during latent infection in the absence
of bacterial replication and continuous exposure
to M. tuberculosis-secreted antigen. Thus, in the
context of a low antigenic load, as in A-TB after
efficacious treatment or in LTBI, the limited
number of effector cells specific to the selected
peptides in the peripheral blood could fall below
the cut-off level, while the number of T-cells
specific to the overlapping peptides covering the
whole proteins, which contain multiple epitopes,
could remain sufficiently high to be detected. This
observation can also be applied to the use of intact
proteins. Moreover, the cut-off value used in this
study was chosen, following ROC analysis, to
maximise the accuracy of A-TB diagnosis,
whereas the cut-off values for the commercially
available assays were probably chosen to maxim-
ise the accuracy of detection of TB infection
[20,21].
The present study has several limitations. First,
this is a pilot study performed in a limited
population; thus, the estimates for sensitivity
and specificity may be imprecise. Second, the in-
vitro positive response to RD1 antigens could be
related to infection with mycobacteria other than
M. tuberculosis, e.g., M. kansasii, M. szulgai, M. fla-
vescens, M. marinum and M. leprae, because the
ESAT-6 gene, or a homologue, is also present in
these related organisms [26,27]. Therefore, it will
be important to evaluate patients with mycobac-
terial diseases other than TB to confirm the
specificity of this assay.
Notwithstanding these limitations, the devel-
opment of a test using RD1 selected peptides may
provide a significant improvement in TB diagno-
sis. Identification and treatment of individuals
with latent M. tuberculosis infection are important
goals in the control of TB, particularly in indus-
trialised countries [4]. Treatment of LTBI requires
that active disease is ruled out. Thus, in the
context of a screening programme, an assay based
on RD1 selected peptides may help to rule out A-
TB among individuals who yield positive results
in either the TST or RD1 overlapping peptides
assay. Ideally, a new testing strategy would
combine an assay based on RD1 intact proteins
or overlapping peptides, which would provide
the advantage of a higher sensitivity for TB
infection, with an assay based on RD1 selected
peptides, which may provide a higher specificity
for the detection of active disease.
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